Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
C
CAMX
Cambiar Aggressive Value ETF
31.4
8
USD
-1.66%
Sector:
Financial
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-1.66%
Monthly Change
-3.41%
6 month change
-3.41%
Year Change
-3.41%
Previous Close
32.0
1
Open
31.4
4
Low
31.4
4
High
31.4
8
Volume
2
Markets
US ETFs
CAMX
Open full chart
Full chart
Overview
All holdings
Heatmap
Top holdings
Market Value
Shares
Weight %
CNC
CENTENE CORPORATION
1.8 M
40.6 K
2.7%
STZ
CONSTELLATION BRANDS, INC.
1.7 M
10.8 K
2.6%
CVX
CHEVRON CORPORATION
1.6 M
9 200.0
2.5%
EL
THE ESTEE LAUDER COMPANIES INC.
1.6 M
14.0 K
2.5%
CMCSA
COMCAST CORPORATION
1.5 M
51.8 K
2.4%
APTV
APTIV PLC
1.5 M
20.0 K
2.4%
Airbus SE
1.4 M
24.8 K
2.2%
SLB
SLB N.V.
1.2 M
25.7 K
1.9%
AXP
AMERICAN EXPRESS COMPANY
1.1 M
3 183.0
1.7%
VSNT
Versant Media Group, Inc.
67.5 K
2 070.8
0.1%
1
2
News
Camurus reports Q4 revenue miss, lowers 2026 outlook
FDA accepts Camurus’ resubmission for acromegaly treatment Oclaiz
Camurus Q3 2025 slides: Revenue up 18% but stock dips on lowered guidance
Camurus cuts 2025 revenue forecast as Buvidal sales miss estimates
Camurus Q2 2025 slides reveal 52% revenue surge and key regulatory milestones
Earnings call transcript: Camurus AB Q2 2025 earnings beat expectations
Camurus Q2 2025 slides: Record revenue and profit amid product portfolio expansion
Camurus’ POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients
Eli Lilly Bets $870 Million on Extended-Release Obesity Drugs
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal ® incretins
Camurus Q1 2025 slides: record profitability despite market challenges
Camurus stock falls on 1Q revenue miss
